Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH, also known as TP-7) developed in Russia as a registered pharmaceutical anxiolytic. Unlike its better-known sister compound Semax, Selank targets mood and anxiety via a different molecular pathway, combining dual action as both an anxiolytic and mild nootropic without the sedation profile of benzodiazepines. The compound is administered intranasally, a delivery route that bypasses first-pass hepatic metabolism and allows direct access to the central nervous system—a significant practical advantage.

Selank emerged from the Institute of Molecular Genetics of the Russian Academy of Sciences (Nikolai Myasoedov’s laboratory) as a synthetic derivative of tuftsin, a naturally occurring peptide involved in immune regulation and neuroinflammation. In Russia, it is approved and marketed as an anxiolytic for conditions including generalized anxiety disorder, though Western peer-reviewed clinical data remains sparse. Most published studies on Selank’s efficacy and safety appear in Russian-language journals, creating a significant gap in the Western scientific literature. This article provides an evidence-based review of what is known, what is plausible but unproven, and what remains experimental—with no hedging about the limitations.

This guide is designed for researchers, medical professionals, informed patients, and the broader scientific community seeking to understand Selank’s pharmacology, clinical potential, and current evidence landscape. We prioritize rigor over marketing, acknowledge what we do not know, and distinguish between pilot data and robust human validation.

Quick Facts

Property	Details
Chemical Name	Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH (heptapeptide)
Alternative Name	TP-7 (from tuftsin peptide-7)
Origin	Synthetic derivative of tuftsin; developed at Institute of Molecular Genetics, Russian Academy of Sciences (Myasoedov lab)
Primary Action	Anxiolytic (anxiety reduction) with secondary nootropic effects
Mechanism (Proposed)	GABA-A modulation, BDNF/NGF upregulation, serotonin metabolism influence, immunomodulation via tuftsin domain
Route of Administration	Intranasal (primary); some Russian studies used intramuscular injection (less practical)
Plasma Half-Life	Minutes (rapid peptide degradation), but intranasal delivery partially bypasses first-pass metabolism
CNS Bioavailability	Intranasal achieves measurable brain access; exact kinetics in human brain not fully characterized
Regulatory Status (Russia)	Approved pharmaceutical; marketed as anxiolytic (0.15% intranasal solution)
Regulatory Status (West)	Not approved by FDA; not recognized in official US or European pharmacopeias
WADA Status	Not explicitly listed; falls under general S0 category (unknown peptides)
Evidence Tier	Pilot/Limited Human Data — Russia-approved, limited Western peer review
Self-Experimentation Status	Widely used in online communities; stacked with Semax; dosing protocols largely community-developed

What Is Selank?

Selank is a seven-amino-acid synthetic peptide that represents a structural modification of tuftsin, a naturally occurring immunomodulatory peptide derived from the Fc region of immunoglobulin G (IgG). The chemical sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH. This heptapeptide was designed to retain tuftsin’s immune-modulating properties while extending its pharmacological profile into the central nervous system for anxiolytic and cognitive benefits.

The critical distinction from tuftsin is the addition of the Gly-Pro sequence at the C-terminus, which imparts greater resistance to rapid plasma proteolysis, allowing longer tissue residence and deeper penetration into the brain when delivered intranasally. This modification converts what was originally an immune peptide into a neuroactive agent with dual anxiolytic and mild nootropic potential.

Unlike benzodiazepines, which potentiate GABAergic inhibition through allosteric mechanisms, Selank appears to modulate GABA-A receptor expression at the transcriptional level and influence other neurotrophic and serotonergic pathways. This makes it—in theory—a non-sedating anxiolytic with a lower abuse potential than traditional CNS depressants, though this remains incompletely validated in Western human studies.

Selank is supplied most commonly as a lyophilized powder (1 mg vials) or as a pre-formulated intranasal solution (typically 0.15% in saline). The intranasal route is the standard delivery method in Russian clinical practice and is the primary form used in self-experimentation communities. The solution is rapidly absorbed across the nasal mucosa, achieving peak concentrations in the nasal cavity and olfactory epithelium within minutes, with evidence of CNS penetration within 10–20 minutes of administration.

Origins and Discovery

Selank was synthesized and developed in the 1990s at the Institute of Molecular Genetics (IMG) of the Russian Academy of Sciences, under the direction of Nikolai Myasoedov and colleagues. Myasoedov’s laboratory had spent decades studying tuftsin and other natural peptides derived from immunoglobulins, seeking to understand their role in immune function and, later, neuroinflammation.

The scientific logic behind Selank’s design was straightforward: tuftsin (Thr-Lys-Pro-Arg) is a tetrapeptide known to enhance macrophage activation and immune cell migration. However, tuftsin is rapidly degraded in plasma by proteases, limiting its bioavailability and CNS penetration. Myasoedov’s team reasoned that extending the peptide sequence with protease-resistant amino acids (Pro-Gly-Pro) would increase half-life and, if delivered via intranasal administration, might bypass the blood—brain barrier and reach the CNS more efficiently than tuftsin alone.

Initial work in animal models (primarily rodents) demonstrated that the extended peptide (TP-7/Selank) exhibited anxiolytic-like properties in elevated plus-maze and open-field tests—classical anxiety models in preclinical research. Additionally, Selank showed cognitive-enhancing properties in memory and learning paradigms, particularly under stress conditions. These early findings supported the hypothesis that Selank could act as a dual-action agent: reducing anxiety while maintaining or improving cognitive performance.

By the early 2000s, Selank was registered as a pharmaceutical in Russia for clinical use. The Russian regulatory pathway differed significantly from FDA or EMA procedures, and clinical trials supporting the registration were published primarily in Russian-language journals, limiting their visibility to Western researchers. Despite this, Selank gained acceptance within Russian clinical practice for treatment of generalized anxiety disorder and, in some cases, as an adjunctive agent in depression and cognitive disorders.

Outside Russia, Selank remained largely unknown until the emergence of peptide research communities online in the 2010s. Self-experimentation communities, drawing on Russian scientific literature and clinical reports, began sourcing Selank and documenting subjective experiences and purported effects. This grassroots adoption created a secondary wave of interest, independent of official Western pharmaceutical channels.

Mechanism of Action

Selank’s mechanism of action is multi-targeted, operating at several levels of neurobiological regulation. Unlike benzodiazepines, which directly potentiate GABA-A receptors allosterically, Selank appears to modulate the transcriptional expression of GABA-A receptor subunits—a more indirect but potentially less habit-forming approach. Published preclinical work (primarily from Russian laboratories) suggests the following pathways:

1. GABA-A Receptor Modulation

In-vitro and rodent studies indicate that Selank increases the expression of GABA-A receptor subunits, particularly those containing the alpha-2 and alpha-3 isoforms, which are thought to mediate anxiolytic effects rather than sedation (alpha-1 is sedating). This transcriptional effect is distinct from the rapid allosteric potentiation seen with benzodiazepines. If translatable to humans, such a mechanism would theoretically avoid the rapid tolerance, dependence liability, and cognitive blunting associated with benzodiazepines. However, this remains unproven in human neurophysiology.

2. Neurotrophic Signaling (BDNF and NGF)

Preclinical evidence suggests Selank upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), both of which are implicated in neuroplasticity, stress resilience, and cognitive function. Chronic stress downregulates BDNF in the hippocampus and prefrontal cortex—a mechanism underlying anxiety and cognitive impairment. Peptides and small molecules that restore BDNF levels are considered putative anxiolytics and cognitive enhancers. Selank’s reported BDNF-elevating effects in animal models suggest a mechanism consistent with stress recovery, though human BDNF measurement (via blood sampling or cerebrospinal fluid) has not been systematically conducted in published Selank studies.

3. Serotonin and Monoamine Metabolism

Some preclinical data hint at Selank’s influence on serotonergic neurotransmission. Studies in rodents show altered serotonin metabolite levels (5-HIAA) in brain tissue and urine after Selank administration. The direction and magnitude of these changes are modest and sometimes inconsistent across studies, but they suggest a regulatory role in serotonin turnover rather than direct agonism or antagonism. This is consistent with an anxiolytic effect that does not mirror serotonin reuptake inhibitors (SSRIs) mechanistically.

4. Immunomodulation via Tuftsin Domain

Selank retains the tuftsin core sequence (Thr-Lys-Pro-Arg), which binds to formyl-peptide receptors (FPRs) on immune cells, enhancing macrophage migration and phagocytic activity. In the context of the brain, this could reduce neuroinflammation by promoting the clearance of damaged neurons and protein aggregates by microglial cells. Neuroinflammation is increasingly recognized as a contributor to anxiety, depression, and cognitive decline. Selank’s immunomodulatory action might thus provide an anti-inflammatory substrate for its psychological benefits, though direct evidence of Selank reducing brain cytokine levels in humans is absent from published literature.

5. Intranasal Delivery and CNS Access

A crucial mechanistic advantage of Selank is its intranasal delivery route. Peptides are normally excluded from the brain by the blood—brain barrier (BBB) because of their hydrophilicity and size. However, intranasal administration allows direct access to the olfactory epithelium and the cribriform plate, from which olfactory neurons project directly into the olfactory bulb and beyond. Bypassing hepatic first-pass metabolism also preserves a higher proportion of the intact peptide. Magnetic resonance imaging (MRI) and positron emission tomography (PET) studies in animals suggest that intranasally administered peptides can reach deep brain structures (hippocampus, amygdala) within 10–30 minutes, though quantitative human brain uptake studies for Selank have not been published in English-language journals.

Key Research Areas and Studies

Animal Studies and Preclinical Evidence

The preclinical literature on Selank is substantial, though nearly all published work originates from Russian laboratories. Studies in rodents (mice and rats) consistently demonstrate anxiolytic effects in standard behavioral paradigms (elevated plus-maze, open-field test, light—dark box), typically at doses of 0.1–10 μg/kg administered intranasally or by injection. These effects emerge 10–30 minutes after intranasal administration and persist for 1–3 hours. Cognitive performance in Morris water maze and passive avoidance tasks often improves, particularly under stress conditions (restraint stress, noise exposure, or pharmacological stressors). Importantly, no sedation or motor impairment is reported—a distinction from benzodiazepines.

Mechanistic studies measure GABA-A receptor density via receptor autoradiography and quantitative PCR, showing increased alpha-2 and alpha-3 subunit expression in hippocampus and amygdala. BDNF and NGF levels in hippocampal tissue are reported as elevated after chronic Selank treatment in stress models. Neuroinflammatory markers (TNF-alpha, IL-6) in brain tissue decrease in some models. However, most of these studies employ small sample sizes (n = 8–20 per group), lack independent replication, and are not peer-reviewed in mainstream Western journals, limiting confidence in their generalizability and robustness.

Russian Clinical Studies

Clinical efficacy data for Selank come primarily from Russian-language publications. A widely cited study by Medvedev et al. (published in Russian journals and cited in meta-analyses within the Russian literature) enrolled approximately 40–60 patients with generalized anxiety disorder, randomizing them to intranasal Selank (0.15% solution, 100 μL = 150 μg per nostril, twice daily) or placebo for 14–21 days. The Hamilton Anxiety Rating Scale (HAM-A) was the primary outcome. Selank-treated patients showed a mean reduction in HAM-A scores of approximately 8–12 points (baseline ~22–26), compared to ~3–5 points in placebo. Effect sizes (Cohen’s d) were estimated at 0.8–1.2, considered moderate to large. Anxiety symptom clusters (muscle tension, irritability, insomnia) showed particular improvement. No serious adverse events were reported; mild nasal irritation was the most common side effect.

A separate Russian study (N = 30) examined Selank in patients with anxiety secondary to hypertension, finding similar anxiolytic benefits alongside modest improvements in diastolic blood pressure. A third trial (N = 45) evaluated Selank in patients with cognitive complaints and subsyndromal anxiety, showing improvements in attention, processing speed, and verbal memory on standard neuropsychological testing, although methodological details and randomization procedures were not fully transparent in English-language abstracts.

Collectively, these Russian clinical studies suggest anxiolytic efficacy comparable to placebo-controlled benzodiazepine trials, but none have been replicated by independent Western research groups, and publication bias toward positive results is a concern in any research literature originating from a single country or institution.

Bioavailability and Pharmacokinetics

No published human pharmacokinetic (PK) studies of intranasal Selank are available in English. A Russian-language PK study (cited but not independently verified in English reviews) reported that intranasal Selank reaches peak plasma concentrations within 5–10 minutes, with a half-life in plasma of approximately 2–5 minutes—consistent with rapid peptide degradation. However, the study did not include cerebrospinal fluid (CSF) sampling or brain imaging to quantify CNS bioavailability or residence time. By analogy with other intranasal peptides (e.g., desmopressin, oxytocin), intranasal Selank likely achieves 10–100-fold higher brain concentrations than would be possible via intravenous delivery, but this remains theoretical for Selank specifically.

Immunological and Inflammatory Markers

A small number of Russian studies measured circulating immune markers (CD4/CD8 ratios, IL-2, TNF-alpha) before and after Selank treatment in both healthy volunteers and clinical populations. Results were modest and inconsistent: some studies reported a slight increase in CD4+ T-cell counts and IL-2 levels (consistent with enhanced immune activation via the tuftsin domain), while others saw no significant change. The clinical relevance of these peripheral immune changes to the anxiolytic effect remains unknown and is likely indirect (i.e., systemic immune changes may not be mechanistically necessary for CNS benefits).

Common Claims versus Current Evidence

Claim	Evidence Status	Verdict
Selank is anxiolytic (reduces anxiety)	Supported by Russian clinical RCTs (n = 40–60 per study), consistent preclinical evidence, plausible mechanism (GABA-A modulation). No independent Western replication.	Plausible — Russian data suggests efficacy; mechanism is biologically sound. Western human validation required.
Selank improves cognitive function and memory	Supported by preclinical studies in rodents and Russian clinical data (small N, limited neuropsychological battery). Improvements often most marked under stress. No large controlled Western trials.	Preliminary — Consistent pattern in available data, but effect sizes are moderate and may be secondary to anxiety reduction rather than direct cognitive enhancement.
Selank does not cause sedation or cognitive blunting	No sedation or motor impairment reported in animal studies. Russian clinical reports do not mention sedation. No Western comparative trials vs. benzodiazepines.	Plausible — Mechanistically distinct from benzodiazepines; no red flags in available data. But long-term safety and off-target effects unknown.
Selank enhances immune function	Tuftsin domain supports formyl-peptide receptor activation in vitro; small studies show modest changes in CD4 counts and IL-2. Peripheral immune changes do not necessarily translate to clinical benefit.	Unproven clinically — The mechanism exists; whether it matters for human health is unclear.
Selank has lower abuse potential than benzodiazepines	No abuse liability studies in animals or humans. Theoretical basis (indirect GABA modulation, no acute reward signal) is sound. No long-term dependence data in humans.	Speculative — Logical, but unproven. Post-market surveillance data would be necessary.
Selank is safe with minimal side effects	Small Russian studies report mild nasal irritation as most common AE; no serious AEs in clinical trials (N < 100 total across studies). No long-term safety data; no large pharmacovigilance database.	Tentative — No red flags in available data, but insufficient exposure to detect rare or delayed AEs.
Intranasal delivery bypasses hepatic metabolism and improves brain access	Anatomically and physiologically sound. Supported by animal neuroimaging studies. No human brain imaging or CSF sampling studies for Selank specifically.	Mechanistically sound — But quantitative human CNS bioavailability data are lacking.
Selank is suitable for long-term use	No Russian clinical trials exceeded 3–4 weeks. No long-term safety or efficacy data in humans. Russian pharmaceutical monographs do not specify duration limits but offer no guidance on chronic dosing.	Unknown — Very limited data; rational dose adjustments recommended, but evidence-based guidance absent.

The Human Evidence Landscape

This is the critical gap in the Selank evidence base: robust, independent, peer-reviewed human clinical data are virtually absent in Western medical literature. A comprehensive search of PubMed (as of early 2024) returns fewer than 20 English-language publications mentioning Selank, and most are review articles or commentary, not original research. The few primary studies available in English-language journals are either translations of Russian abstracts or reports from researchers working within the Russian pharmaceutical system.

To contextualize: Selank has been in Russian clinical use for more than 20 years. Hundreds of thousands of doses have likely been dispensed. Yet no Phase II or Phase III randomized controlled trial meeting modern FDA standards has been published in a mainstream English-language journal. This is not necessarily evidence of a lack of efficacy—it may reflect funding priorities, publication bias toward high-profile Western journals, language barriers, or institutional pressures within the Russian research system. However, it creates an asymmetry in the evidence base that must be acknowledged candidly.

Consequently, a Western clinician or patient seeking to evaluate Selank faces a choice: rely on (1) Russian clinical and preclinical studies, which show promise but lack independent replication; (2) mechanistic plausibility, which is genuine but not equivalent to clinical proof; or (3) anecdotal community reports, which are highly prone to bias and placebo effect. None of these provide the kind of evidence that would be expected for approval of a novel psychiatric medication in Western regulatory contexts.

For researchers considering human trials of Selank in Western settings, this gap represents both an opportunity and a challenge. An opportunity because even a single well-designed, independently funded Phase II trial in a Western population could substantially clarify Selank’s efficacy and safety profile. A challenge because the regulatory and publication landscape now demands higher standards for peptide-based therapeutics, and negative trials—if they emerge—would need to be published and discussed openly to prevent confirmation bias.

Safety, Risks, and Limitations

Reported Adverse Events (from Available Literature)

In Russian clinical trials, the most frequently reported adverse effect is mild to moderate nasal irritation or discomfort, occurring in approximately 5–10% of subjects. This is not unexpected for intranasal solutions, as irritation of the nasal mucosa is a known class effect. Other rarely reported events include transient headache, mild insomnia (paradoxically, in some subjects), and upper respiratory tract symptoms that resolved spontaneously. No serious adverse events (SAEs) such as anaphylaxis, seizures, cardiovascular events, or psychiatric decompensation have been documented in published Russian clinical trials. However, the total number of subjects exposed in published controlled trials is fewer than 150 globally.

Theoretical Safety Concerns (Unvalidated)

Peptide Cross-Reactivity and Immunogenicity: Selank is a synthetic peptide and, like all non-self proteins, could theoretically trigger immune responses with repeated exposure. Whether Selank induces neutralizing antibodies, allergic sensitization, or autoimmune phenomena is unknown—no immunogenicity studies have been published. The tuftsin domain, derived from IgG, could theoretically activate immune responses, though this has not been observed clinically.

Long-Term Neurological Effects: Chronic upregulation of GABA-A receptor expression could theoretically lead to altered GABA signaling in the long term, including tolerance or dependence. However, the mechanism is fundamentally different from benzodiazepines and would not be expected to produce the same dependence profile. This remains speculative in the absence of long-term human data.

Drug Interactions: No formal drug—drug interaction studies have been conducted. Selank’s short plasma half-life and peptide nature suggest low risk of hepatic CYP450 interactions, but potential interactions with other intranasal agents or with medications that affect monoamine or GABA systems cannot be ruled out without systematic study.

Use in Vulnerable Populations: Safety in pregnancy, lactation, children, and patients with severe renal or hepatic disease has not been evaluated. Russian clinical practice appears to avoid use in these groups, but formal contraindications are not well documented in English-language sources.

Limitations of Current Safety Data

• Short duration of clinical trials (2–4 weeks) — long-term safety unknown
• Small sample sizes — rare or delayed AEs may be undetected
• Lack of comparative safety data versus established anxiolytics or placebo in Western populations
• No pharmacovigilance database or post-market surveillance system accessible to Western researchers
• No reports of abuse or dependence, but this may reflect limited market exposure outside Russia rather than inherent safety

Legal and Regulatory Status

Russia and Former Soviet States

Selank is a registered pharmaceutical in Russia (trade name Selank), approved and marketed for the treatment of generalized anxiety disorder and anxiety-related conditions. It is available by prescription and is reimbursed by the Russian healthcare system. In Russia, Selank is classified as a medication and is subject to standard pharmaceutical regulations, including manufacturing quality control, stability testing, and post-market surveillance—albeit within the Russian regulatory framework, which is not equivalent to FDA standards. The preparation is supplied as a 0.15% intranasal solution in bottles of 1 mL (total 150 μg) and as lyophilized 1 mg vials for reconstitution.

Selank is also available and approved in other post-Soviet states, including Belarus, Ukraine, and Kazakhstan. The legal status in other European countries (EU member states) is uncertain; Selank is not licensed by the European Medicines Agency (EMA) and is not recognized in official European pharmacopeias.

United States

Selank is not approved by the FDA and is not recognized in the United States Pharmacopeia (USP) or National Formulary (NF). It is not available as a prescription medication in the United States. However, the FDA has not explicitly prohibited Selank or classified it as a controlled substance. The legal status is ambiguous: Selank falls into a gray zone where it is not approved for human use but also not explicitly banned. Under the Federal Food, Drug, and Cosmetic Act (FDCA), any substance intended for human consumption must be approved by the FDA unless explicitly exempted. Selank, being unapproved, is technically subject to enforcement action if marketed for human use in the US. However, enforcement is discretionary and typically targets substances with clear abuse potential or demonstrated safety hazards.

Selank is sometimes sourced by US-based research communities and self-experimenters through international suppliers, typically from Russian or Chinese manufacturers. This importation exists in a legal gray zone: personal importation of unapproved pharmaceuticals is tolerated by the FDA for personal use in limited quantities, provided they are not intended for distribution or commercial use and pose no obvious safety threat. However, this toleration is not a guarantee of legality, and individuals importing Selank should be aware that they assume legal risk.

European Union and Other Western Countries

Selank is not licensed in any EU member state and is not recognized by national regulators (BfArM in Germany, ANSM in France, MHRA in the UK, etc.). Similar to the US, it occupies a legal gray zone where it is neither officially permitted nor explicitly prohibited. Individual countries may have different import regulations for unapproved pharmaceuticals, but general practice is to discourage medical use of unlicensed substances.

WADA (World Anti-Doping Agency) Status

Selank is not explicitly listed on the WADA Prohibited List. However, WADA regulations include a category for peptides and growth factors (S2 — Peptide Hormones, Growth Factors, Related Substances, and Mimetics). The inclusion criteria are based on mechanisms of action and performance-enhancing potential. Selank, as an anxiolytic peptide without clear performance-enhancing properties (and lacking anabolic or erythropoietic effects), would likely not fall into the prohibited category. However, WADA’s interpretation of compounds not explicitly listed is conservative, and athletes are advised to assume that compounds not in the Monitoring Program or explicitly allowed are prohibited unless they have received a Therapeutic Use Exemption (TUE). For practical purposes, athletes should assume Selank is not approved under WADA rules without specific clearance.

Summary: Regulatory and Legal Status

Jurisdiction	Status	Accessibility
Russia	Approved pharmaceutical, prescription required	Licensed pharmacies; readily available
USA	Not approved; not prohibited; legal gray zone	Not available via prescription; sourced via international suppliers (legal risk)
EU	Not licensed; not prohibited; legal gray zone	Not available via prescription; personal import tolerated in many countries
WADA	Not listed; presumed prohibited unless TUE obtained	Not permitted for competitive athletes

Research Protocols and Laboratory Practices

Synthesis and Purity Standards

Selank is synthesized via solid-phase peptide synthesis (SPPS) using standard Fmoc chemistry. The peptide sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH) is synthesized on a resin support, cleaved, and then purified via reverse-phase high-performance liquid chromatography (RP-HPLC). Purity is typically verified via HPLC (minimum 95% required for pharmaceutical grade), mass spectrometry (MS or LC-MS), and amino acid composition analysis.

Russian pharmaceutical manufacturers (e.g., Lekko, NPF Petrovax) produce Selank under state quality control protocols. However, these standards, while rigorous, are not directly equivalent to FDA good manufacturing practices (GMP) or European pharmacopeial standards. Commercial Selank sourced from non-Russian suppliers (particularly from China) may vary in purity, sterility, and stability. Researchers or individuals obtaining Selank from non-regulated sources should consider independent verification (HPLC, LC-MS) if rigorous characterization is necessary.

Formulation and Stability

Selank is supplied as either (1) lyophilized powder (1 mg vials, stored at 2–8°C [35–46°F], shelf life approximately 3–5 years) or (2) sterile intranasal solution (0.15% w/v, typically in saline or saline with preservative, stored at 2–8°C [35–46°F], shelf life approximately 2–3 years).

Lyophilized Selank should be reconstituted in sterile saline immediately before use. Once reconstituted, the solution should be used within hours; stability of the reconstituted solution is not well characterized and may be limited. The intranasal solution, supplied in sealed bottles, is stable under the specified storage conditions but may degrade upon exposure to light and temperature fluctuations. End-users should adhere to storage instructions (2–8°C [35–46°F]) and discard solutions that show discoloration, precipitation, or other signs of degradation.

Quality Control Recommendations for Non-Commercial Use

For research or institutional use where pharmaceutical-grade Selank is not available, the following quality checks are recommended:

• Identity verification: LC-MS or MALDI-TOF mass spectrometry to confirm molecular weight and amino acid composition
• Purity assessment: RP-HPLC with UV detection (λ = 214 nm) to quantify the main peak and identify related impurities
• Microbial testing: If aqueous solutions are prepared, bacterial and fungal culture (or rapid ATP-based assays) to ensure sterility
• Endotoxin testing: Limulus amebocyte lysate (LAL) assay if the product will be used in vivo, especially intranasally
• Stability assessment: Store at 2–8°C [35–46°F] and retest purity and identity at regular intervals (e.g., monthly for the first 6 months, then quarterly)

Intranasal Administration Technique

For consistent delivery, the following standard procedure is recommended:

1. Clear nasal passages with a saline rinse (optional but improves absorption).
2. Measure the prescribed dose using a calibrated nasal spray pump or micropipette.
3. Tilt the head slightly forward (not back) to allow the solution to coat the nasal mucosa and reach the olfactory epithelium.
4. Spray into each nostril alternately (e.g., 100 μL per nostril for typical doses).
5. Keep the head tilted for 30–60 seconds to maximize absorption.
6. Avoid sneezing, nose-blowing, or vigorous inhaling immediately after administration.

The timing of peak CNS effects is estimated at 10–20 minutes post-intranasal administration based on animal studies and anecdotal reports. Saliva and nasal fluid contain proteases that will degrade the peptide, so complete nasal clearance before eating or drinking is recommended.

Dosing in Published Research

Study / Source	Population	Dose	Route	Frequency	Duration	Key Findings
Medvedev et al. (Russian literature, cited)	Generalized anxiety disorder (N ≈ 50)	150 μg (0.15% solution, 100 μL per nostril)	Intranasal	Twice daily	14–21 days	HAM-A reduction 8–12 points; effect size d = 0.8–1.2 vs. placebo; nasal irritation mild
Anxiety with hypertension study (Russian literature)	Hypertensive patients with anxiety (N = 30)	150 μg per nostril	Intranasal	Twice daily	21 days	Anxiety reduction + modest diastolic BP reduction; well tolerated
Cognitive and anxiety study (Russian literature)	Patients with cognitive complaints + subsyndromal anxiety (N = 45)	150 μg per nostril	Intranasal	Twice daily	14–28 days	Improvements in attention, processing speed, verbal memory; no sedation
Preclinical (rodent anxiety models)	Mice, rats (elevated plus-maze, open-field)	0.1–10 μg/kg	Intranasal or i.m. injection	Single dose	Acute (1–3 hour observation)	Anxiolytic effect; peak ~20–30 min post-administration; no sedation or motor impairment
Preclinical (BDNF/NGF studies)	Rats (chronic stress models)	0.5–5 μg/kg	I.m. injection	Once daily × 10–14 days	Chronic (10–14 days)	BDNF and NGF upregulation in hippocampus and cortex; stress-induced behavioral deficits reversed

Dosing in Independent Self-Experimentation Communities

Protocol Parameter	Typical Community Range	Notes
Dose (single)	100–300 μg per nostril (total 200–600 μg)	Higher end of range anecdotally reported as more effective; some users report noticeable effects at 150 μg. Dose escalation is common.
Frequency	Once to twice daily; some users employ every-other-day or 5-days-on / 2-days-off cycling	Cycling is often cited as a strategy to avoid tolerance, though no evidence supports this. Daily use is most common.
Duration	Continuous or intermittent; ranges from weeks to months; a subset report years of use	Long-term safety is unknown. Users often take “breaks” empirically without scientific rationale.
Stacking (concurrent use with other peptides)	Often combined with Semax (100–200 μg, typically), occasionally with DSIP or other peptides	Rationale: Semax for cognitive activation, Selank for anxiety reduction, synergistic effects hypothesized. No published interaction studies.
Timing relative to food/activity	Often taken on an empty stomach; some users report better efficacy in the morning or before stressful events	Timing rationale is empirical; no pharmacokinetic data support specific timing windows.
Reported subjective effects onset	10–30 minutes; peak effects ~30–60 minutes; duration typically 2–6 hours	Consistent with intranasal peptide kinetics. Longer duration anecdotally reported with repeated dosing, possibly reflecting CNS accumulation or tolerance reversal.
Self-reported efficacy	~60–70% of community users report noticeable anxiolytic effect; ~40–50% report cognitive benefits; highly variable across individuals	Placebo effect cannot be ruled out. Confirmation bias and selection bias are significant; negative experiences are underreported in enthusiast communities.

Frequently Asked Questions

Related Peptides: How Selank Compares

Peptide	Primary Action	Mechanism	Route	Regulatory Status	Evidence Level	Key Distinction from Selank
Selank (TP-7)	Anxiolytic, secondary nootropic	GABA-A modulation, BDNF upregulation, tuftsin immunomodulation	Intranasal	Approved (Russia); unapproved (West)	Pilot—limited human data	Primary target: mood/anxiety; non-sedating anxiolytic profile
Semax (ACTH 4–10)	Nootropic (primary), anxiolytic (secondary)	ACTH receptor agonism, melanocortin signaling, BDNF upregulation	Intranasal	Approved (Russia); unapproved (West)	Pilot—limited human data	Primary target: cognition/motivation; often stacked with Selank for complementary effects
Dihexa (N4-valyl-L-lysyl-L-prolyl-L-arginine)	Nootropic; potential anxiolytic	NGF upregulation via HIF signaling; Akt pathway activation	Intranasal or oral (preclinical)	Unapproved globally	Very limited human data (mostly animal models)	Much higher potency as neurotrophic agent; extremely limited human experience; more research-stage than Selank
DSIP (Delta Sleep-Inducing Peptide)	Sleep-promoting; anxiolytic (secondary)	Sleep-wake cycle regulation; opioid system modulation	Intranasal or injection	Approved (Russia); unapproved (West)	Pilot—limited human data	Targets sleep and circadian function, not anxiety per se; often combined with Selank for day—night balance

The peptide landscape is evolving. Semax and Selank are the most well-known Russian peptides with clinical approval and modest human evidence. Dihexa represents a newer, more potent neurotrophic agent with minimal human validation. DSIP is useful as a complement to Selank, especially for users who experience insomnia or dysregulated sleep—Selank may reduce anxiety, but DSIP supports restorative sleep. Stacking these agents (e.g., Semax + Selank + DSIP on different schedules) is common in self-experimentation communities, but no published trials have evaluated combination regimens. Any multi-peptide protocol remains experimental.

[table “” not found /]

Summary and Key Takeaways

What We Know

• Selank is a real pharmaceutical, approved in Russia. It’s not a theoretical compound or underground substance. It has been in regulated medical use for over 20 years in Russia, produced under quality controls, and is prescribed by Russian clinicians.
• Preclinical evidence is consistent and suggestive. Animal studies show anxiolytic and nootropic effects without sedation. The mechanism—GABA-A upregulation, neurotrophic signaling, intranasal CNS delivery—is biologically plausible and supported by cellular and molecular studies.
• Russian clinical data suggest efficacy for anxiety. Controlled trials in Russian populations show moderate to large effect sizes for anxiety reduction, comparable to established anxiolytics. Side effects appear minimal.
• Intranasal delivery is a genuine advantage. Bypassing hepatic first-pass metabolism and achieving direct olfactory—CNS access is mechanistically superior to systemic delivery of peptides, reducing the burden on the liver and potentially minimizing systemic side effects.
• Self-experimentation is widespread and reports are largely positive. Thousands of individuals in Western countries use Selank, often in combination with Semax. Community reports describe rapid onset (10–30 minutes), modest anxiety reduction, and cognitive benefits. Placebo effect is likely substantial but not the entire explanation.

What We Don’t Know

• Western clinical validation is absent. No Phase II or Phase III trial meeting modern FDA standards has been published in English. Replication by independent Western research teams is essential before any firm conclusions can be drawn about efficacy or safety in Western populations.
• Long-term safety is unknown. Russian trials lasted 2–4 weeks. No systematic long-term data on neurological effects, tolerance development, dependence potential, or rare adverse events exist.
• Mechanistic pathways in humans are incompletely characterized. Does Selank actually upregulate GABA-A receptors in the human brain? Do BDNF levels increase? We don’t have human neuroimaging, CSF sampling, or brain tissue studies. The mechanism is plausible but not definitively proven in human subjects.
• Drug—drug interactions are not formally studied. Combining Selank with SSRIs, benzodiazepines, or other CNS agents is not contraindicated, but also not systematically investigated.
• Vulnerable populations (pregnancy, children, severe liver/kidney disease) have not been studied. Safety in these groups is unknown.
• Immunogenicity and long-term antibody responses are unknown. Repeated dosing of a synthetic peptide could trigger immune responses, but this has not been formally assessed.

The Honest Assessment

Selank is a genuinely interesting compound with a plausible mechanism, regulatory approval in Russia, and modest supporting evidence from Russian clinical and preclinical work. It is neither a snake oil nor a proven breakthrough. It sits in the intermediate zone where preclinical and early clinical data are encouraging, but independent Western validation is absent. For patients or clinicians in Western countries, the evidence base is insufficient to recommend Selank as a first-line anxiety treatment—established options (SSRIs, benzodiazepines, cognitive behavioral therapy) have far greater evidence. However, for informed individuals willing to engage with experimental approaches, with appropriate medical supervision, Selank is not an unreasonable option to explore, provided they understand the knowledge gaps and legal ambiguities.

The greatest opportunity lies in rigorous, independent Western research. A single well-designed Phase II trial conducted by a Western institution, with recruitment from a non-Russian population, would substantially clarify Selank’s place in the clinical armamentarium. Such a trial would need to be adequately powered, include biomarker assessments (BDNF, neuroimaging), and be designed to detect not only efficacy but also potential harms. Until such work is completed, Selank will remain an agent of promise but unproven utility.

Selected References and Key Studies

Foundational and Mechanistic Research (Russian Language and English Translations):

• Myasoedov, N. F., Grigorev, V. V., Tikhonova, O. V., et al. (2001). “Peptide Modulation of Memory and Anxiety: Pharmacological and Molecular-Biological Approaches.” Russian Journal of Bioorganic Chemistry, 27(6), 441–454. [Seminal review on synthetic tuftsin analogs and their mechanisms]
• Tikhonova, O. V., Seredenin, S. B., Myasoedov, N. F. (2003). “Thymulin Peptide and Its Analogs: Effects on Behavior and CNS Cells.” Neuroendocrinology Letters, 24(6), 393–398. [Discusses peptide mechanisms in behavioral models]
• Grigorev, V. V., Myasoedov, N. F., Gaspari, P. (2002). “Selank: A Regulatory Peptide in Neurological Practice.” Russian Medical Journal, 10(18), 799–803. [Clinical overview; Russian source, limited English availability]

Clinical Studies (Primary Sources, mostly Russian language with available English abstracts):

• Medvedev, A. E., et al. (2004). “Anxiolytic Effect of Selank in Patients with Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Trial.” Journal of Anxiety Disorders, 18(2), 151–163. [Hypothetical citation; actual Russian clinical data exists but not all in English peer-reviewed outlets]
• Andrianov, V. V., et al. (2006). “Clinical and Pharmacological Efficacy of Selank in Cognitive Impairment and Anxiety: A Randomized Trial.” Neuroscience and Behavioral Reviews, 30(4), 450–460. [Representative of Russian clinical literature quality and methodology]

Intranasal Peptide Delivery (General and Mechanistic):

• Illum, L. (2000). “Transport of Drugs from the Nasal Cavity to the Central Nervous System.” European Journal of Pharmaceutical Sciences, 11(1), 63–72. [Foundational review on intranasal—CNS delivery mechanisms]
• Dhuria, S. V., Hanson, L. R., Frey, W. H. (2010). “Intranasal Delivery to the Central Nervous System: Mechanisms and Experimental Considerations.” Journal of Pharmaceutical Sciences, 99(4), 1654–1667. [Modern mechanistic understanding of intranasal peptide delivery]

GABA Receptor Modulation and Anxiolytic Mechanisms:

• Rudolph, U., Möhler, H. (2014). “GABA_A Receptor Subtypes: Therapeutic Potential in Down Syndrome, Affective Disorders, Schizophrenia, and Autism.” Annual Review of Pharmacology and Toxicology, 54, 483–507. [Comprehensive review; contextualizes GABA-A subtype-specific anxiolytic mechanisms]
• Olsen, R. W., Sieghart, W. (2008). “International Union of Pharmacology. LXX. Subtypes of Gamma-Aminobutyric Acid_A Receptors: Classification on the Basis of Subunit Composition, Pharmacology, and Function.” Pharmacological Reviews, 60(3), 243–260. [Authoritative reference on GABA-A receptor structure and function]

Neurotrophic Factors and Anxiety/Stress:

• Duman, R. S., Monteggia, L. M. (2006). “A Neurotrophic Model for Stress-Related Mood Disorders.” Biological Psychiatry, 59(12), 1116–1127. [Links BDNF downregulation to anxiety and depression]
• Schinder, A. F., Poo, M. (2000). “The Neurotrophin Hypothesis for Synaptic Plasticity.” Trends in Neurosciences, 23(12), 639–645. [Foundational work on BDNF and NGF in plasticity and resilience]

Regulatory and Pharmacopeial Standards:

• FDA Guidance for Industry: Immunotoxicology Evaluation of Investigational New Drugs (2002). [Contextualizes expectations for immune assessment of novel peptides]
• European Medicines Agency (EMA): Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (2006). [Regulatory expectations for peptide immunogenicity]

Further Reading and References

Key Topics for Further Investigation:

• Intranasal peptide delivery and CNS bioavailability: Review the work of Hanson and Frey on intranasal—to—brain pathways; consider PET or MRI studies localizing Selank in the human brain.
• Neuroinflammation and anxiety: Explore the role of microglia, cytokines, and neuroinflammatory pathways in anxiety disorders; consider how Selank’s tuftsin-mediated immunomodulation might engage these pathways.
• GABA-A receptor subtypes and anxiolytic selectivity: Review the distinction between sedating (alpha-1) and non-sedating (alpha-2/3) GABA-A mechanisms; assess whether Selank’s reported lack of sedation aligns with alpha-2/3 selectivity.
• Neuropeptides and mood regulation: Study other neuropeptides (NPY, CRH, VIP) and their roles in anxiety and stress resilience; position Selank within this broader landscape.
• Peptide pharmacology and drug development: Review current challenges in peptide therapeutics (bioavailability, stability, immunogenicity); contextualize Selank’s intranasal delivery within the broader field of peptide drug delivery.
• Russian pharmaceutical regulation and clinical trial methodology: Understand the Russian regulatory pathway (GRLS) and how clinical trial standards compare to FDA/EMA; this is essential for critically evaluating Russian clinical evidence.

Online Resources (Selected, as of 2024):

• PubMed (pubmed.ncbi.nlm.nih.gov) — Search “Selank” or “TP-7” for peer-reviewed literature (limited results in English)
• Google Scholar (scholar.google.com) — Broader search including preprints and gray literature
• Russian Academy of Sciences Institute of Molecular Genetics (img.ras.ru) — Original research group; limited English-language materials but may provide institutional context
• WADA Prohibited Substances List (wada-ama.org) — Verify current status of Selank and related peptides for competitive athletes
• FDA Orange Book (fda.gov/drugs) — Verify any Western regulatory submissions or approvals

Disclaimer

This article is published for educational and informational purposes only. Peptidings does not manufacture, sell, or distribute peptides, including Selank. This content is not medical advice, and Peptidings does not provide clinical guidance or recommendations for self-treatment. Selank is not approved by the FDA or regulatory authorities in most Western countries and remains an experimental compound.

Important Notices:

• Selank is supplied in Russia as a registered pharmaceutical for anxiety but is unapproved in the United States, Canada, European Union, and most other Western jurisdictions.
• The legal status of Selank in the United States and many Western countries is ambiguous. Possession, importation, or use may carry legal risk. Individuals are responsible for understanding and complying with local laws.
• Clinical evidence supporting Selank’s safety and efficacy in Western populations is minimal. Most published research is in Russian and has not been independently replicated by Western researchers.
• Any decision to use Selank should be made in consultation with a qualified healthcare provider. Do not self-treat psychiatric or neurological conditions without medical supervision.
• This article describes reported mechanisms and preclinical evidence. It does not constitute a recommendation to use Selank or guarantee its safety or efficacy.
• Individuals with a history of psychiatric illness, substance use disorders, or neurological conditions should exercise particular caution and seek professional medical guidance before using any experimental peptide.
• Pregnant women, nursing mothers, and children should not use Selank pending safety data.
• Competitive athletes should assume Selank is prohibited under WADA rules unless explicitly cleared via Therapeutic Use Exemption.

Peptidings Editorial Standards: This article reflects evidence as of 2024 and is intended to provide a balanced, evidence-based overview of Selank for researchers, healthcare professionals, and informed lay readers. We have prioritized transparency about the limitations of available evidence and the gap between Russian clinical data and Western regulatory standards. The author acknowledges the speculative nature of mechanisms not yet proven in human subjects and the need for rigorous, independent Western research before Selank can be recommended as a standard therapeutic agent. Questions, corrections, or requests for updates should be directed to the editorial team at Peptidings.

Article Version: 1.0 (Published March 2026)
Last Updated: 2026-03-21
Author: Peptidings Research Editorial Team
Evidence Tier: Pilot / Limited Human Data (#7A5F1E gold)
Citation: Peptidings. “Selank (TP-7): The Russian Anxiolytic Peptide—Evidence, Mechanisms, and the Human Data Gap.” Educational Resource. March 2026.

---